Follow
An ongoing clinical test for Ebola drug trial was halted because of decline in patients affected by the virus in West Africa. This trial was testing brincidofovir at a clinic located in Monrovia, Liberia.
According to the Chimerix, the drug developer, they will no longer participate in this clinical trial. Chief Executive Dr. Michelle Berrey of Chimerix states less patients were not making any conclusions with their study. Furthermore, the company shipped 140 drugs initially to Liberia and lesser than 10 were seen to have good prognosis. Moreover, the World Health Organization reported last week that the number of new Ebola cases decreased to a hundred in the most affected countries in Africa.
